David L Porter

List of Publications by Year
in descending order

85	18,627	94381 37	62565 80
papers	citations	h-index	g-index

86	86	86	16146
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Decade-long leukaemia remissions with persistence of CD4+ CAR T cells. Nature, 2022, 602, 503-509.	13.7	369
2	Day 4 vs. day 12 G-CSF administration following reduced intensity peripheral blood allogeneic stem cell transplant. Journal of Oncology Pharmacy Practice, 2022, , 107815522210807.	0.5	0
3	Salvage therapy with basiliximab and etanercept for severe steroidâ€refractory acute graftâ€versusâ€host disease. American Journal of Hematology, 2022, 97, .	2.0	1
4	Process, resource and success factors associated with chimeric antigen receptor T-cell therapy for multiple myeloma. Future Oncology, 2022, 18, 2415-2431.	1.1	2
5	CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication. Journal of Clinical Investigation, 2021, 131, .	3.9	52
6	Leucovorin Rescue After Methotrexate Graft-Versus-Host Disease Prophylaxis Shortens the Duration of Mucositis, Time to Neutrophil Engraftment, and Hospital Length of Stay. Transplantation and Cellular Therapy, 2021, 27, 431.e1-431.e8.	0.6	1
7	BET bromodomain protein inhibition reverses chimeric antigen receptor extinction and reinvigorates exhausted T cells in chronic lymphocytic leukemia. Journal of Clinical Investigation, 2021, 131, .	3.9	45
8	Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature. Transplantation and Cellular Therapy, 2021, 28, 18.e1-18.e1.	0.6	4
9	Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells. Blood, 2021, 138, 166-166.	0.6	2
10	Incidence and Predictors of Sars-Cov-2 Antibody Responses Following COVID-19 Vaccination in Allogeneic Stem Cell Transplant Recipients. Blood, 2021, 138, 2888-2888.	0.6	1
11	Real World Survival Outcomes of CPX-351 Versus Venetoclax and Azacitadine for Initial Therapy in Adult Acute Myeloid Leukemia. Blood, 2021, 138, 795-795.	0.6	7
12	Optimizing Chimeric Antigen Receptor T-Cell Therapy for Adults With Acute Lymphoblastic Leukemia. Journal of Clinical Oncology, 2020, 38, 415-422.	0.8	162
13	Immunotherapy with cells (article not eligible for CME credit). Hematology American Society of Hematology Education Program, 2020, 2020, 590-597.	0.9	1
14	Cytokine release syndrome and neurotoxicity following CAR T-cell therapy for hematologic malignancies. Journal of Allergy and Clinical Immunology, 2020, 146, 940-948.	1.5	78
15	Advances in CAR T Therapy for Hematologic Malignancies. Pharmacotherapy, 2020, 40, 741-755.	1.2	11
16	Risk of invasive fungal infections in patients with <scp>highâ€risk MDS</scp> and <scp>AML</scp> receiving hypomethylating agents. American Journal of Hematology, 2020, 95, 792-798.	2.0	20
17	Long-Term Outcomes From a Randomized Dose Optimization Study of Chimeric Antigen Receptor Modified T Cells in Relapsed Chronic Lymphocytic Leukemia. Journal of Clinical Oncology, 2020, 38, 2862-2871.	0.8	102
18	Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lymphoma. , 2020, 8, e001235.		11

#	Article	IF	Citations
19	Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells. Blood, 2020, 136, 30-32.	0.6	4
20	Tocilizumab for the treatment of severe steroid-refractory acute graft-versus-host disease of the lower gastrointestinal tract. Bone Marrow Transplantation, 2019, 54, 212-217.	1.3	34
21	Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)â€“an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT). Bone Marrow Transplantation, 2019, 54, 1868-1880.	1.3	86
22	Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8+ T cells and impede CAR T-cell efficacy. Blood, 2019, 134, 44-58.	0.6	118
23	Accelerating chimeric antigen receptor therapy in chronic lymphocytic leukemia: The development and challenges of chimeric antigen receptor Tâ€cell therapy for chronic lymphocytic leukemia. American Journal of Hematology, 2019, 94, S10-S17.	2.0	22
24	Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus,) Tj ETQq0 0 0 rgBT /Overlock 10 Tf methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203). Lancet Haematology,the, 2019, 6, e132-e143.	2.2	200
25	Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Transplantation and Cellular Therapy. Biology of Blood and Marrow Transplantation, 2019, 25, e76-e85.	2.0	85
26	Extended CCR5 Blockade for Graft-versus-Host Disease Prophylaxis Improves Outcomes of Reduced-Intensity Unrelated Donor Hematopoietic Cell Transplantation: A Phase II Clinical Trial. Biology of Blood and Marrow Transplantation, 2019, 25, 515-521.	2.0	24
27	Oral Vancomycin Prophylaxis Is Highly Effective in Preventing Clostridium difficile Infection in Allogeneic Hematopoietic Cell Transplant Recipients. Clinical Infectious Diseases, 2019, 68, 2003-2009.	2.9	54
28	CD19-targeting CAR T cell immunotherapy outcomes correlate with genomic modification by vector integration. Journal of Clinical Investigation, 2019, 130, 673-685.	3.9	78
29	A Characterization of Bridging Therapies Leading up to Commercial CAR T-Cell Therapy. Blood, 2019, 134, 4108-4108.	0.6	14
30	Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nature Medicine, 2018, 24, 563-571.	15.2	1,150
31	Pharmacodynamic Monitoring Predicts Outcomes of CCR5 Blockade as Graft-versus-Host Disease Prophylaxis. Biology of Blood and Marrow Transplantation, 2018, 24, 594-599.	2.0	6
32	Erythropoietic protoporphyria in an adult with sequential liver and hematopoietic stem cell transplantation: A case report. American Journal of Transplantation, 2018, 18, 745-749.	2.6	20
33	Chimeric antigen receptor (CAR) T therapies for the treatment of hematologic malignancies: clinical perspective and significance. , 2018, 6, 137.		182
34	Early positron emission tomography/computed tomography as a predictor of response after CTL019 chimeric antigen receptor â€“T-cell therapy in B-cell non-Hodgkin lymphomas. Cytotherapy, 2018, 20, 1415-1418.	0.3	45
35	Toward dual hematopoietic stem-cell transplantation and solid-organ transplantation for sickle-cell disease. Blood Advances, 2018, 2, 575-585.	2.5	7
36	Higher Donor Apheresis Blood Volumes Are Associated with Reduced Relapse Risk and Improved Survival in Reduced-Intensity Allogeneic Transplantations with Unrelated Donors. Biology of Blood and Marrow Transplantation, 2018, 24, 1203-1208.	2.0	1

#	Article	IF	Citations
37	Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells. Nature, 2018, 558, 307-312.	13.7	574
38	Checkpoint Inhibitors Augment CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Relapsed B-Cell Acute Lymphoblastic Leukemia. Blood, 2018, 132, 556-556.	0.6	106
39	Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate. Blood, 2018, 132, 298-298.	0.6	73
40	Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8+ T Cells and Impede CAR T Cell Efficacy. Blood, 2018, 132, 235-235.	0.6	2
41	Outcomes of Allogeneic Stem Cell Transplantation for AML and MDS Based on Pre-Transplant MRD Status By Next-Generation Sequencing. Blood, 2018, 132, 2134-2134.	0.6	1
42	Clinical and immunologic impact of CCR5 blockade in graft-versus-host disease prophylaxis. Blood, 2017, 129, 906-916.	0.6	56
43	Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes. Journal of Clinical Oncology, 2017, 35, 1154-1161.	0.8	495
44	The promise of chimeric antigen receptor T cells (<scp>CART</scp>s) in leukaemia. British Journal of Haematology, 2017, 177, 13-26.	1.2	17
45	Cellular kinetics of CTL019 in relapsed/refractory B-cell acute lymphoblastic leukemia and chronic lymphocytic leukemia. Blood, 2017, 130, 2317-2325.	0.6	273
46	Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas. New England Journal of Medicine, 2017, 377, 2545-2554.	13.9	1,390
47	Chimeric Antigen Receptor T Cells and Hematopoietic Cell Transplantation: How Not to Put the CART Before the Horse. Biology of Blood and Marrow Transplantation, 2017, 23, 235-246.	2.0	76
48	Clinical Efficacy of Anti-CD22 Chimeric Antigen Receptor T Cells for B-Cell Acute Lymphoblastic Leukemia Is Correlated with the Length of the Scfv Linker and Can be Predicted Using Xenograft Models. Blood, 2017, 130, 807-807.	0.6	4
49	Infusion of CD3/CD28 costimulated umbilical cord blood T cells at the time of single umbilical cord blood transplantation may enhance engraftment. American Journal of Hematology, 2016, 91, 453-460.	2.0	7
50	Unrelated donors are associated with improved relapseâ€free survival compared to related donors in patients with myelodysplastic syndrome undergoing reduced intensity allogeneic stem cell transplantation. American Journal of Hematology, 2016, 91, 883-887.	2.0	3
51	Autologous stem cell transplantation in first complete remission may not extend progressionâ€free survival in patients with peripheral T cell lymphomas. American Journal of Hematology, 2016, 91, 672-676.	2.0	27
52	Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology American Society of Hematology Education Program, 2016, 2016, 567-572.	0.9	158
53	Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia. Cancer Discovery, 2016, 6, 664-679.	7.7	811
54	Ibrutinib enhances chimeric antigen receptor T-cell engraftment and efficacy in leukemia. Blood, 2016, 127, 1117-1127.	0.6	381

#	Article	IF	Citations
55	Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation. Biology of Blood and Marrow Transplantation, 2016, 22, 1961-1967.	2.0	30
56	<scp>CAR</scp><scp>T</scp>â€cells merge into the fast lane of cancer care. American Journal of Hematology, 2016, 91, 146-150.	2.0	36
57	Nelarabine, cyclosphosphamide and etoposide for adults with relapsed Tâ€cell acute lymphoblastic leukaemia and lymphoma. British Journal of Haematology, 2016, 174, 332-334.	1.2	21
58	Toxicities and Outcomes of Ibrutinib-Treated Patients in the United States: Large Retrospective Analysis of 621 Real World Patients. Blood, 2016, 128, 3222-3222.	0.6	16
59	Biomarkers of Response to Anti-CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Chronic Lymphocytic Leukemia. Blood, 2016, 128, 57-57.	0.6	18
60	Pilot Study of Anti-CD19 Chimeric Antigen Receptor T Cells (CTL019) in Conjunction with Salvage Autologous Stem Cell Transplantation for Advanced Multiple Myeloma. Blood, 2016, 128, 974-974.	0.6	28
61	A drive through cellular therapy for CLL in 2015: allogeneic cell transplantation and CARs. Blood, 2015, 126, 478-485.	0.6	37
62	Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood, 2015, 126, 1033-1040.	0.6	565
63	Evolution to plasmablastic lymphoma evades CD19â€directed chimeric antigen receptor T cells. British Journal of Haematology, 2015, 171, 205-209.	1.2	83
64	High Graft CD8 Cell Dose Predicts Improved Survival and Enables Better Donor Selection in Allogeneic Stem-Cell Transplantation With Reduced-Intensity Conditioning. Journal of Clinical Oncology, 2015, 33, 2392-2398.	0.8	52
65	Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Science Translational Medicine, 2015, 7, 303ra139.	5.8	1,402
66	Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients. Journal of Antimicrobial Chemotherapy, 2015, 70, 2078-2083.	1.3	4
67	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. Biology of Blood and Marrow Transplantation, 2015, 21, 151-158.	2.0	49
68	R-CHOP or R-HyperCVAD With or Without Autologous Stem Cell Transplantation for Older Patients With Mantle Cell Lymphoma. Clinical Lymphoma, Myeloma and Leukemia, 2015, 15, 92-97.	0.2	9
69	Improved Survival After Transplantation of More Donor Plasmacytoid Dendritic or NaÃ¯ve T Cells From Unrelated-Donor Marrow Grafts: Results From BMTCTN 0201. Journal of Clinical Oncology, 2014, 32, 2365-2372.	0.8	77
70	Current concepts in the diagnosis and management of cytokine release syndrome. Blood, 2014, 124, 188-195.	0.6	2,080
71	Early Donor Chimerism Levels Predict Relapse and Survival after Allogeneic Stem Cell Transplantation with Reduced-Intensity Conditioning. Biology of Blood and Marrow Transplantation, 2014, 20, 1758-1766.	2.0	52
72	A Phase I Study Using Single Agent Birinapant in Patients with Relapsed Myelodysplastic Syndrome and Acute Myelogenous Leukemia. Blood, 2014, 124, 3758-3758.	0.6	9

#	Article	IF	Citations
73	T Cells Engineered with a Chimeric Antigen Receptor (CAR) Targeting CD19 (CTL019) Have Long Term Persistence and Induce Durable Remissions in Children with Relapsed, Refractory ALL. Blood, 2014, 124, 380-380.	0.6	14
74	Chimeric Antigen Receptorâ€"Modified T Cells for Acute Lymphoid Leukemia. New England Journal of Medicine, 2013, 368, 1509-1518.	13.9	3,021
75	Chimeric Antigen Receptor T Cells Directed Against CD19 Induce Durable Responses and Transient Cytokine Release Syndrome in Relapsed, Refractory CLL and ALL. Blood, 2012, 120, 717-717.	0.6	10
76	Chimeric Antigen Receptorâ€"Modified T Cells in Chronic Lymphoid Leukemia. New England Journal of Medicine, 2011, 365, 725-733.	13.9	3,067
77	Chimeric Antigen Receptor Therapy for B-cell Malignancies. Journal of Cancer, 2011, 2, 331-332.	1.2	88
78	Graft-Vs-Lymphoma (GVL) Induction with Allogeneic Hematopoietic Stem Cell Transplantation (SCT) for Primary Cutaneous T Cell Lymphomas (CTCL).. Blood, 2010, 116, 4574-4574.	0.6	0
79	Cellular Adoptive Immunotherapy After Autologous and Allogeneic Hematopoietic Stem Cell Transplantation. Cancer Treatment and Research, 2009, 144, 497-537.	0.2	5
80	Initial Safety, Pharmacokinetic and Pharmacodynamic Data from a Phase I Clinical Trial of Systemic C-MYB Antisense Oligodeoxynucleotide in Subjects with Refractory Hematologic Malignancies. Blood, 2008, 112, 4033-4033.	0.6	0
81	A phase 1 trial of donor lymphocyte infusions expanded and activated ex vivo via CD3/CD28 costimulation. Blood, 2006, 107, 1325-1331.	0.6	209
82	Donor leukocyte infusions in myeloid malignancies: new strategies. Best Practice and Research in Clinical Haematology, 2006, 19, 737-755.	0.7	34
83	Novel approaches to allogeneic stem cell therapy. Expert Opinion on Biological Therapy, 2001, 1, 3-15.	1.4	10
84	Graft-Versus-Tumor Induction With Donor Leukocyte Infusions as Primary Therapy for Patients With Malignancies. Journal of Clinical Oncology, 1999, 17, 1234-1234.	0.8	124
85	Stem cell transplantation for metastatic breast cancer: analysis of tumor contamination. Medical Oncology and Tumor Pharmacotherapy, 1999, 16, 279-288.	1.0	15